Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation

Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Endocrinol
Главные авторы: Pöll, Florian, Lehmann, Diana, Illing, Susann, Ginj, Mihaela, Jacobs, Stefan, Lupp, Amelie, Stumm, Ralf, Schulz, Stefan
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2010
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/
https://ncbi.nlm.nih.gov/pubmed/20051480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы